Poxel Reports Financial Update for Cash and Revenue for the Full Year 2020 and Provides Corporate Update Feb 12, 2021
Poxel Announces Additional Positive Phase 2a Results, and Phase 2b Plan for PXL770, an Oral First-in-Class AMPK Activator, in NASH Dec 14, 2020
Poxel Presents Phase 1b Clinical Results for PXL065 and New Preclinical Data for PXL770 at AASLD The Liver Meeting® 2020 Nov 16, 2020
